Brain and other CNS tumors are the most common types of cancer in children aged 0–14 years, with an annual age-adjusted incidence rate of 5.47 per 100,000, and also the leading cause of cancer-related death in this age group, having recently surpassed leukemia in the US cancer registry. Brain cancer among the adult population accounts for 1.4% of all new cancers and 2.8% of all cancer deaths, with an annual incidence of 6.4 cases per 100,000 adults. Taking into consideration all primary brain and nervous system tumors in adults, the US incidence rate is estimated to be 29.18 per 100,000 population with approximately one-third of tumors being malignant and the remainder being benign or borderline malignant [1, 2]. The most common intracranial tumor is brain metastasis. They are ten times more frequent than primary brain tumors, and their incidence is increasing during the past decades, most probably due to the increased availability of brain imaging. More than 75% of the primary brain tumors are gliomas and meningiomas.
This is a preview of subscription content, log in to check access.
Ostrom TQ, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18(suppl_5):v1–v75CrossRefGoogle Scholar
National Cancer Institute, SEER Cancer Statistics Review (CSR) 1975–2014. Released April 2017Google Scholar
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefGoogle Scholar
Norden AD, Wen YP, Kesari S (2005) Brain metastases. Curr Opin Neurol 18:654–661PubMedGoogle Scholar
Diener-West M, Dobbins TW, Phillips TL et al (1989) Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 16(3):669–673CrossRefGoogle Scholar
Lagerwaard FJ, Levendag PC, Nowak PJ et al (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43(4):795–803CrossRefGoogle Scholar
Riemenschneider MJ, Jeuken JW, Wesseling P et al (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120(5):567–584CrossRefGoogle Scholar
Towner RA, Jensen RL, Colman H et al (2012) ELTD1, a potential new biomarker for gliomas. Neurosurgery 72:77CrossRefGoogle Scholar
Stewart LA (2002) Chemotherapy in adult high- grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311):1011–1018CrossRefGoogle Scholar
Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489CrossRefGoogle Scholar
Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63(4):275–286CrossRefGoogle Scholar
Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neuro-Oncol 70(2):183–202CrossRefGoogle Scholar
Perry A, Banerjee R, Lohse CM et al (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12(2):183–190PubMedGoogle Scholar
Zamora C, Castillo M (2017) Sellar and parasellar imaging. Neurosurgery 80(1):17–38PubMedGoogle Scholar